Scientists discuss potential strategies for developing future therapeutic farnesoid-X-receptor (FXR) modulators to overcome current limitations for fibrosis diseases, providing new perspectives for enterohepatic and metabolic diseases treatment.
[Acta Pharmacologica Sinica]
Sorry, but the selected Zotpress account can't be found.